MARKET

CLYYF

CLYYF

Celyad Oncology
EXMKT
0.527
NaN%
Opening 09:30 02/10 EST
OPEN
--
PREV CLOSE
0.527
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.527
52 WEEK LOW
0.527
MARKET CAP
21.85M
P/E (TTM)
-2.8773
1D
5D
1M
3M
1Y
5Y
1D
Celyad Oncology SA GAAP EPS of -$0.09
Seeking Alpha · 09/26/2025 19:21
Celyad Oncology Reports First Half 2025 Results
TipRanks · 09/26/2025 03:50
Weekly Report: what happened at CLYYF last week (0908-0912)?
Weekly Report · 09/15/2025 10:16
Weekly Report: what happened at CLYYF last week (0901-0905)?
Weekly Report · 09/08/2025 10:18
Weekly Report: what happened at CLYYF last week (0825-0829)?
Weekly Report · 09/01/2025 10:15
Weekly Report: what happened at CLYYF last week (0818-0822)?
Weekly Report · 08/25/2025 10:21
Weekly Report: what happened at CLYYF last week (0811-0815)?
Weekly Report · 08/18/2025 10:16
Weekly Report: what happened at CLYYF last week (0804-0808)?
Weekly Report · 08/11/2025 10:20
More
About CLYYF
Celyad Oncology SA, formerly Celyad SA is a Belgium-based company. The Company is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The Company's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). It also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).

Webull offers Celyad Oncology SA stock information, including EXMKT: CLYYF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLYYF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLYYF stock methods without spending real money on the virtual paper trading platform.